Abstract
This commentary article conveys the views of the board of the Nanomedicine and Nanoscale Delivery Focus Group of the Controlled Release Society regarding the decision of the United States National Cancer Institute (NCI) in halting funding for the Centers of Cancer Nanotechnology Excellence (CCNEs), and the subsequent editorial articles that broadened this discussion.
Original language | English |
---|---|
Journal | Drug Delivery and Translational Research |
Volume | 10 |
Issue number | 3 |
Pages (from-to) | 726–729 |
Number of pages | 4 |
ISSN | 2190-393X |
DOIs | |
Publication status | Published - Jun 2020 |
MoE publication type | A1 Journal article-refereed |
Fields of Science
- CANCER
- CHEMOTHERAPY
- Cancer therapy
- Clinical translation
- Nanomedicine
- Nanotechnology
- PACLITAXEL
- Reproducibility
- THERAPY
- TUMOR
- 3122 Cancers
- 221 Nano-technology
- 317 Pharmacy